news

CUPERTINO, Calif., March 1, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2011. Total revenues were $8.9 million for the three months ended December 31, 2011, up from $8.5 million for the three months ended December 31, 2010.  Net loss for the three […]

CUPERTINO, Calif., Feb. 24, 2012 /PRNewswire/ — In conjunction with DURECT Corporation‘s (Nasdaq: DRRX) fourth quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, March 1, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., Feb. 23, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) James E. Brown, President and CEO, will present at the RBC Capital Markets‘ Global Healthcare Conference on Wednesday, February 29 at 8:00 a.m. Eastern Time.  The conference is being held

CUPERTINO, Calif., Feb. 7, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 14 at 10:30 a.m. Eastern Time.  The conference is being held at the Waldorf-Astoria Hotel in New York City.  (Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., Jan. 30, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today reported that Takeda (through Nycomed) has given notice that it is returning its development and commercialization rights to POSIDUR™ (SABER™-Bupivacaine) in Europe and their other licensed territories.  Takeda acquired its rights to POSIDUR through its acquisition of Nycomed in September, 2011.  POSIDUR is

Conference call to be held January 6 at 8:30 a.m. ET CUPERTINO, Calif., Jan. 5, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today top-line results from the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).  POSIDUR is a post-operative pain relief depot that utilizes DURECT‘s

CUPERTINO, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) Jim Brown, President and CEO, will present at the Credit Suisse Health Care Conference in Phoenix, Arizona on Wednesday, November 9 at 3:00 p.m. Pacific Time. A

CUPERTINO, Calif., Nov. 3, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2011. Total revenues were $8.1 million for the three months ended September 30, 2011 and 2010. Net loss for the three months ended September 30, 2011 was $5.0 million, compared to

CUPERTINO, Calif., Oct. 26, 2011 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2011 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, November 3, 2011 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:

CUPERTINO, Calif., Sept. 6, 2011 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial). POSIDUR is a post-operative pain relief depot that utilizes DURECT’s patented SABER(TM) technology to